Skip to main content
  • Register
  • Help
  • Contact us

Xintela AB (XINT) NPV

Sell:2.98 SEK Buy:2.99 SEK Change: 0.06 SEK (1.98%)
Market closed |  Prices as at close on 5 May 2021 | Switch to live prices |
Sell:2.98 SEK
Buy:2.99 SEK
Change: 0.06 SEK (1.98%)
Deal now Deal for just £11.95 per trade in a Fund and Share Account
Market closed |  Prices as at close on 5 May 2021 | Switch to live prices |
Sell:2.98 SEK
Buy:2.99 SEK
Change: 0.06 SEK (1.98%)
Market closed |  Prices as at close on 5 May 2021 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Fund and Share Account
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Xintela AB (Xintela) is a Sweden-based biomedical company engaged in the fields of regenerative medicine and cancer, with particular focus on cartilage damage and brain tumors. In the field of regenerative medicine, the Company focuses on cartilage damage and osteoarthritis, and in the field of brain tumors, its focuses on the development of a treatment for glioblastoma, an aggressive tumor. The Company has developed therapeutic antibodies, which bind to cancer cells. It has also developed XINMARK, a marker technology which consists of specific proteins, which work as recognition flags on the surface of certain cells. The markers make it possible to identify and select certain types of stem cells which can develop into cartilage cells.

Contact details

Address:
Medicon Village, Scheeletorget 1
LUND
22381
Sweden
Telephone:
+46 (46) 2756500
Website:
xintela.se/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
XINT
ISIN:
SE0007756903
Market cap:
234.21 million SEK
Shares in issue:
73.97 million
Sector:
Biotechnology
Exchange:
Stockholm Stock Exchange
Country:
Sweden
Currency:
Swedish Krona
Indices:
n/a

Key personnel

  • Gregory Batcheller
    Executive Chairman of the Board
  • Evy Lundgren-Akerlund
    Chief Executive Officer
  • Gunnar Telhammar
    Chief Financial Officer
  • Sven Kili
    Chief Operating Officer, Chief Medical Officer, Executive Director
  • Rickard Mosell
    Head of Business Development
  • Thomas Areschoug
    Business Development Manager
  • Caroline Ehrencrona
    Director Clinical Development and Regulatory Affairs
  • Carl-Magnus Hogerkorp
    Production Manager
  • Liselotte Theorell
    Director Product Development and Quality Management

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Fund and Share Account

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.